Non-viable Lactobacillus Reuteri DSMZ 17648 (Pylopass™) As A New Approach To Helicobacter Pylori Control In Humans

Effect Decrease
Trial Design Cohort
Trial Length 1-2 Weeks
Number of Subjects 22
Gender Both Genders
Age Range 45-64
Notes for this study:
In a single blind study where after two weeks placebo in both groups there was then either a continuation of placebo or administration of _L. reuteri_ for two weeks, supplementation of the DSMZ 17648 strain at 2x10^10^ CFU daily was able to significantly reduce breath urea in _H. pylori_ infected persons who did not reach the criteria for eradication therapy.

The benefits of two weeks supplementation persisted for 24 weeks, and there was no difference in potency between freeze-dried and spray-dried bacteria.

Inhibition Of Helicobacter Pylori Infection In Humans By Lactobacillus Reuteri ATCC 55730 And Effect On Eradication Therapy: A Pilot Study

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 32
Gender Both Genders
Age Range 45-64
Notes for this study:
Supplementation of a single chewable tablet containing 10^8^ CFU of _L. reuteri_ ATCC 55730 daily (two hours after a meal) for 28 days was associated with significant improvements on a breath urea test, reducing scores by 13% relative to a 3% increase seen in placebo.

Subjective symptoms of gastrointestinal infection were also reduced.